Who Paid My Doc
Rethymic
Drug Congenital Athymia
NDC 72359-001-01
General payments
$805,377
Research payments
$2,607,591
Through program year 2025, $805,377 in general payments and $2,607,591 in research payments were reported against Rethymic (Congenital Athymia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $438,724 | 30 |
| 2025 | Research | $1,074,870 | 51 |
| 2024 | General | $39,861 | 15 |
| 2024 | Research | $1,532,721 | 85 |
| 2023 | General | $244,674 | 212 |
| 2022 | General | $82,118 | 8 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
265 general · 136 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.